Patients
arrhythmia
ONCOLOGY, DISEASE, SOLID TUMORS, ARRHYTHMIA
Twenty-four patients with solid tumors were screened for eligibility and 19 of them underwent treatment. Screening failures were mainly due to abnormal clinical chemistry values (N = 4) and unstable symptomatic arrhythmia (N = 1). The first patient was enrolled on February 20, 2019 and the last patient’s last visit was on December 14, 2021. Two patients were excluded from the analysis. The safety data set included 17 patients. The activity analysis set included 16 patients, as one patient (the first enrolled), had no measurable disease. The CONSORT diagram is shown in Fig. CONSORT diagramBaseline characteristics of the study populationData are n (%), mean (SD; standard deviation). ECOG = Eastern Cooperative Oncology Group. N = number of subjects. Percentages are based on the number of subjects within each cohort